期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 34, 期 3, 页码 167-177出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2013.01.001
关键词
neurodegeneration; glutathione; glutamate; schizophrenia; bipolar disorder; Alzheimer's; Parkinson's; mania; psychosis; anxiety; addiction; obsessive-compulsive disorder; depression; autism; cannabis; trichotillomania
资金
- AstraZeneca
- Eli Lilly
- Organon
- Pfizer
- Servier
- Wyeth
- Medical Benefits Fund of Australia
- Bristol-Myers Squibb
- GlaxoSmithKline
- Novartis
- Mayne Pharma
- Rebecca L. Cooper Medical Research Foundation
- Brain and Behaviour Foundation
- Simons Autism Foundation
- Stanley Medical Research Institute
- Lilly
- National Health and Medical Research Council (NHMRC)
- Society for Bipolar and Depressive Disorders (ASBDD)/Servier grant
N-Acetylcysteine (NAC) targets a diverse array of factors germane to the pathophysiology of multiple neuropsychiatric disorders including glutamatergic transmission, the antioxidant glutathione, neurotrophins, apoptosis, mitochondrial function, and inflammatory pathways. This review summarises the areas where the mechanisms of action of NAC overlap with known pathophysiological elements, and offers a precis of current literature regarding the use of NAC in disorders including cocaine, cannabis, and smoking addictions, Alzheimer's and Parkinson's diseases, autism, compulsive and grooming disorders, schizophrenia, depression, and bipolar disorder. There are positive trials of NAC in all these disorders, and although many of these require replication and are methodologically preliminary, this makes it one of the most promising drug candidates in neuropsychiatric disorders. The efficacy pattern of NAC interestingly shows little respect for the current diagnostic systems. Its benign tolerability profile, its action on multiple operative pathways, and the emergence of positive trial data make it an important target to investigate.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据